Co-expression of Hif1alpha and CAIX is Associated with Poor Prognosis in Oral Squamous Cell Carcinoma Patients

Overview

Journal J Oral Pathol Med

Specialties Dentistry
Pathology

Date 2009 Sep 29

PMID 19780905

Citations 27

Authors

A W Eckert

M H W Lautner

A Schutze

K Bolte

M Bache

M Kappler

J Schubert

H Taubert

U Bilkenroth

Affiliations

Soon will be listed here.

Abstract

Background: This study investigates the prognostic impact of the expression of hypoxia-inducible factor 1alpha (Hif1alpha) and carbonic anhydrase IX (CAIX) detected by immunohistochemistry in oral squamous cell carcinoma (OSCC).

Methods: Statistical analysis of immunohistochemical results with clinical parameters including survival outcomes was performed for 80 OSCC patients.

Results: Patients with a low expression of both proteins survived on average 54.8 months, whereas those with an increased expression of Hif1alpha in their tumors combined with a low expression of CAIX survived on average only 37.6 months (P = 0.026). In multivariate Cox's regression hazard analysis, again patients with a low expression of Hif1alpha/CAIX had the best prognosis, whereas patients with increased Hif1alpha and low CAIX expression carried a 4.97-fold increased risk of tumor-related death (P = 0.042).

Conclusion: A co-detection of low Hif1alpha/CAIX expression is significantly correlated with a better prognosis for OSCC patients, which may have implications for therapy options for these patients.

Citing Articles

The carbonic anhydrase inhibitor acetazolamide inhibits urinary bladder cancers via suppression of β-catenin signaling.

Matsue T, Gi M, Shiota M, Tachibana H, Suzuki S, Fujioka M Cancer Sci. 2022; 113(8):2642-2653.

PMID: 35723039 PMC: 9357660. DOI: 10.1111/cas.15467.

Understanding metabolic alterations and heterogeneity in cancer progression through validated immunodetection of key molecular components: a case of carbonic anhydrase IX.

Takacova M, Kajanova I, Kolarcikova M, Lapinova J, Zatovicova M, Pastorekova S Cancer Metastasis Rev. 2022; 40(4):1035-1053.

PMID: 35080763 PMC: 8825433. DOI: 10.1007/s10555-021-10011-5.

Dual-targeting vaccine of FGL1/CAIX exhibits potent anti-tumor activity by activating DC-mediated multi-functional CD8 T cell immunity.

Chai D, Qiu D, Shi X, Ding J, Jiang N, Zhang Z Mol Ther Oncolytics. 2022; 24:1-13.

PMID: 34977338 PMC: 8688948. DOI: 10.1016/j.omto.2021.11.017.

Current Understanding of the HIF-1-Dependent Metabolism in Oral Squamous Cell Carcinoma.

Eckert A, Kappler M, Grosse I, Wickenhauser C, Seliger B Int J Mol Sci. 2020; 21(17).

PMID: 32846951 PMC: 7504563. DOI: 10.3390/ijms21176083.

Prognostic value of CAIX expression in oral squamous cell carcinoma: a systematic review and meta-analysis.

Lorenzo-Pouso A, Gallas-Torreira M, Perez-Sayans M, Chamorro-Petronacci C, Alvarez-Calderon O, Takkouche B J Enzyme Inhib Med Chem. 2020; 35(1):1258-1266.

PMID: 32466707 PMC: 7337009. DOI: 10.1080/14756366.2020.1772250.